Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (September 2023)
24 slides from Netramark's investor presentation, September 2023
Slide 1: Corporate Presentation
CSE: AIAI CORPORATE PRESENTATION OTCQB: AINMF September 2023 FRA: 8TV
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement presentation has been prepared by NetraMark Holdings Inc. (“NetraMark” or the “Company”) and conta
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: Our Vision and Goals
The NetraMark vision is to have a material OUR VISION AND GOALS impact on the current 12% clinical trial success rate and serve the pharmaceutical industry’s demands for the efficient development of novel therapeutics and medicines. CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 5: The Team
We have assembled a highly experienced leadership team OFFICERS George Achilleos Josh Spiegel Dr. Joseph Geraci Awards / Partnerships Chief Executive Officer President Chief Technology Officer / Chief Scientific Officer and Director George is a seasoned Business Executive with 25+ 25-plus years of e
Slide 6: The Pharmaceutical Industry
The AI pharmaceutical space THE PHARMACEUTICAL INDUSTRY Key areas of application: 1. There is a real challenge identifying molecules that address disease 2. Clinical trial de-risking CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 7: The Opportunity
We believe there is significant opportunity to improve the clinical trial process and reduce the associated cost BASIC DRUG PRE- FDA POST-APPROVAL CLINICAL TRIALS RESEARCH & RESEARCH DISCOVERY CLINICAL REVIEW MONITORING PHASE I PHASE II PHASE III PHASE IV THE OPPORTUNITY From drug discovery through
Slide 8: The Market
The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 Number of interventional clinical studies, past 12 months1 450,000 399,522 400,000 2,500 362,500 350,000 325,771 293,254 2,000 300,000 262,299 250,000 233,124 1,500 205,335 2,300 200,000 181,22
Slide 9: Clinical Trial Problems & Risks
The core issues • Phase 2 trials not necessarily predictive of later phase CLINICAL TRIAL PROBLEMS & RISKS pivotal studies • Observed or potential adverse events that can derail programs • Lack of separation in indications known for placebo response • Unexpected results for diseases with heterogenou
Slide 10: The Challenge of Using AI for Clinical Trials
The challenge of using AI for clinical trials THE CHALLENGE FOR AI The challenge centers around the ability to apply AI methods to small datasets and extract statistically significant insights that can be utilized to enrich future studies and reduce the associated costs CSE: AIAI OTCQB: AINMF FRA: 8
Slide 11: Over 95% of Trials Have Less Than 1,000 Participants
Over 95% of trials have less than 1,000 participants Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging. TEI OFNO R A I Cumulative # of trials by anticipated # of participants (1999 – 2021)* 1-100 94,607 HEA
Slide 12: Traditional View of Existing Data
Traditional view of existing data Unless there is a massive effect size in the ETHODS data or a large sample size, traditional methods have limitations TA E ADLAM Traditional methods: • T-Tests and ANOVA HN • Chi-Square Test IA T R A D I TT • Logistic Regression • Linear Regression • Feature selecti
Slide 13: The NetraMark Approach – Attractor AI
The Attractor AI view of Genetic A NetraMark innovation - Attractor AI Non Small Cell Lung Cancer data THE NETRAMARK APPROACH – ATTRACTOR AI At the core of NetraAI exists a new paradigm: Attractor AI NetraAI will identify patients that require different treatments, react differently to placebo or to
Slide 14: The NetraMark Workflow
The NetraMark Workflow 1 Transcriptomics NetraAI Genomics Proteomics Clinical Trial Data THE WORKFLOW Methylation Clinical NetraPlacebo NetraGPT Scales NetraPlay Imaging Optimize Study Instant Explainability of Response and Power Results Step 1 Step 2 Step 3 Step 4 Data preparation and ingestion Net
Slide 15: Use Case – Schizophrenia Trial
Sponsor Brief: Phase IIa Schizophrenia Trial Project objectives Data included clinical scales: CGI-S, LOF, Strauss- • Characterize patient response to optimize USE CASE – SCHIZOPHRENIA TRIAL Carpenter Level of Functioning; mITT, PANSS, and in addition physiological measurements including heart rate,
Slide 16: Use Case – Schizophrenia Trial Results
Using NetraAI to drive better results in late phase studies By Combining NetraAI Hypotheses A Roadmap To Maximize Endpoint Effect Size is Generated USE CASE – SCHIZOPHRENIA TRIAL p = .04 • Assumption - a scaled-up version of the clinical trial consisting of 100 people in both the active and placebo
Slide 17: Use Case – Pancreatic Cancer – FFX vs GnP Response
Project Brief: USE CASE – PANCREATIC CANCER – FFX VS GnP RESPONSE FFX vs GnP Response Project objectives • Demonstrate improved survival of Data consisted of RNA-Seq from 208 patient tumors with pancreatic ductal adenocarcinoma. The treatment program and pancreatic cancer through a precision respons
Slide 18: Use Case – Pancreatic Cancer Response Rates
USE CASE – PANCREATIC CANCER – FFX VS GnP RESPONSE Using NetraAI to drive better results in late phase studies Demonstrating the significant changes in effect size that occur when one can characterize patients with respect to drug response. The upshot is that more patients will have a positive impac
Slide 19: The NetraMark Offering
NetraAI Decision Support Solutions • Phase I offering The role of NetraAI * • NetraAI evaluates existing Phase I data and client MOA. Recommends THE NETRAMARK OFFERING assays (methylation, RNA-Seq, fMRI, EEG, microbiome) and outcome measures (clinical scales) to optimize the upcoming pre pivotal (Ph
Slide 20: The Go To Market Approach
The Target Engagement Biotech or pharma company programs with clinical data in an indication of experience in these areas: • Oncology • Neurology THE GO TO MARKET APPROACH • Psychiatry • Metabolic • Rare & Orphan Disorders The Target Audience Leverage high level relationships & attend disease specif
Slide 21: The Business Model
Current Year YTD Results THE BUSINESS MODEL Building the sales pipeline 60 Leads in the sales pipeline Leverage leadership pharmaceutical network 20+ CRO channel partner discussions Pharma Targeting outreach Aggressive conference schedule Build CRO channel strategy Sales pipeline lead list build to
Slide 22: The Market Comps
The Pharmaceutical AI sector is producing high valuation multiples Comparison Estimated Revenue Pre-Money Valuation Valuation / Rev Multiple Owkin1 2020 ~ $12.15M Nov 2021 ~ $1.12B ~ 92X ConcertAI1 2022 ~ $53M Mar 2022 ~ $1.75B ~ 33X THE MARKET COMPS AITIA2 ~ $14M Jan 2020 ~ $120M ~ 8.6X PathAI3 ~ $
Slide 23: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 24: Statutory Rights of Action
STATUTORY RIGHTS OF ACTION In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is or
NetraMark Holdings — Investor Presentation (September 2023) on 6ix